Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Kündgen

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Leukemia Research|September 18, 2012
Prognostic scoring systems in MDSUlrich Germing, Andrea Kündgen
American Journal of Hematology|June 8, 2012
Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient databaseOfir Shukron, Vladimir Vainstein, Andrea Kündgen, et al.
Annals of Hematology|January 11, 2007
Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinibMatthias Drechsler, Barbara Hildebrandt, Andrea Kündgen, et al.
Onkologie|June 23, 2012
Diagnosis and therapy of myelodysplastic syndromes in Germany: a retrospective multicenter analysisNorbert Gattermann, Andrea Kündgen, Lenka Kellermann, et al.
Expert Review of Hematology|July 30, 2019
Novel therapies in low- and high-risk myelodysplastic syndromeUlrich Germing, Thomas Schroeder, Jennifer Kaivers, et al.
European Journal of Haematology|October 10, 2013
The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in GermanyNorbert Gattermann, Andrea Kündgen, Lenka Kellermann, et al.
Haematologica|September 2, 2004
No increase in age-specific incidence of myelodysplastic syndromesUlrich Germing, Corinna Strupp, Andrea Kündgen, et al.
British Journal of Haematology|May 12, 2015
In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over timeMichael Lauseker, Jennifer Schemenau, Corinna Strupp, et al.
Leukemia Research|February 3, 2009
Impact on survival of different treatments for myelodysplastic syndromes (MDS)Kathrin Nachtkamp, Andrea Kündgen, Corinna Strupp, et al.
Leukemia Research|May 9, 2012
Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registryJudith Neukirchen, Frank Fox, Andrea Kündgen, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Leukemia Research|September 18, 2012
Prognostic scoring systems in MDSUlrich Germing, Andrea Kündgen
American Journal of Hematology|June 8, 2012
Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient databaseOfir Shukron, Vladimir Vainstein, Andrea Kündgen, et al.
Annals of Hematology|January 11, 2007
Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinibMatthias Drechsler, Barbara Hildebrandt, Andrea Kündgen, et al.
Onkologie|June 23, 2012
Diagnosis and therapy of myelodysplastic syndromes in Germany: a retrospective multicenter analysisNorbert Gattermann, Andrea Kündgen, Lenka Kellermann, et al.
Expert Review of Hematology|July 30, 2019
Novel therapies in low- and high-risk myelodysplastic syndromeUlrich Germing, Thomas Schroeder, Jennifer Kaivers, et al.
European Journal of Haematology|October 10, 2013
The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in GermanyNorbert Gattermann, Andrea Kündgen, Lenka Kellermann, et al.
Haematologica|September 2, 2004
No increase in age-specific incidence of myelodysplastic syndromesUlrich Germing, Corinna Strupp, Andrea Kündgen, et al.
British Journal of Haematology|May 12, 2015
In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over timeMichael Lauseker, Jennifer Schemenau, Corinna Strupp, et al.
Leukemia Research|February 3, 2009
Impact on survival of different treatments for myelodysplastic syndromes (MDS)Kathrin Nachtkamp, Andrea Kündgen, Corinna Strupp, et al.
Leukemia Research|May 9, 2012
Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registryJudith Neukirchen, Frank Fox, Andrea Kündgen, et al.
Pageof 4